SCHEMBL5556045

SCHEMBL5556045

CCN(CC)c1ccc2c(c1)OC(C(C)C)C(=O)N(Cc1cc(Cl)cc(Cl)c1)C2C(=O)Nc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
NOX1 Q9Y5S8 2/20 0.36
GHSR Q92847 6/20 0.35
PKM P14618 2/20 0.33
MAPT P10636 7/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
TP53 P04637 3/20 0.33
KDM4E B2RXH2 3/20 0.33
NFKB1 P19838 2/20 0.33
NFKB2 Q00653 2/20 0.33
RELA Q04206 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
GAA P10253 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5562363 0.89 MEN1 (0.40) ALDH1A1LMNAHTTL3MBTL1NPC1
SCHEMBL5556632 0.87 MAPT (0.40) ALDH1A1LMNAHTTL3MBTL1NPC1
SCHEMBL5556588 0.87 KCNA5 (0.33)
SCHEMBL5562516 0.87 FAAH (0.40) ALDH1A1LMNAHTTL3MBTL1MEN1
SCHEMBL5563041 0.85 GAA (0.39) ALDH1A1LMNAHTTL3MBTL1NPC1
SCHEMBL5556041 0.85 TSHR (0.38) ALDH1A1HTTL3MBTL1NPC1RAB9A
SCHEMBL5556105 0.80 MC4R (0.40) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL5561387 0.79 GAA (0.40) ALDH1A1LMNAHTTL3MBTL1NPC1
SCHEMBL5556785 0.79 P2RX7 (0.38) ALDH1A1MAPTTP53GAA
SCHEMBL5555839 0.78 KCNA5 (0.40) MEN1KMT2AMAPTTP53NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631296-B1 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE HOFFMANN LA ROCHE (CH) 2007-04-25 EP disclosed
US-7060698-B2 Benzoxazepinone derivatives HOFFMANN-LA ROCHE INC. (US) 2006-06-13 US disclosed
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. HOFFMANN-LA ROCHE INC. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. BACE1, BACE2, PSEN1 ALDH1A1 724/4885LMNA 759/4885HTT 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.